- Home
- HCWB vs MTVA Comparison
HCWB vs MTVA Comparison
Compare HCWB & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- MTVA
- Stock Information
- Founded
- HCWB 2018
- MTVA 2014
- Country
- HCWB United States
- MTVA United States
- Employees
- HCWB N/A
- MTVA N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- MTVA
- Sector
- HCWB Health Care
- MTVA
- Exchange
- HCWB Nasdaq
- MTVA NYSE
- Market Cap
- HCWB 17.2M
- MTVA 16.8M
- IPO Year
- HCWB 2021
- MTVA N/A
- Fundamental
- Price
- HCWB $0.39
- MTVA $1.60
- Analyst Decision
- HCWB
- MTVA Strong Buy
- Analyst Count
- HCWB 0
- MTVA 1
- Target Price
- HCWB N/A
- MTVA $12.00
- AVG Volume (30 Days)
- HCWB 18.3M
- MTVA 23.0K
- Earning Date
- HCWB 03-31-2025
- MTVA 03-27-2025
- Dividend Yield
- HCWB N/A
- MTVA N/A
- EPS Growth
- HCWB N/A
- MTVA N/A
- EPS
- HCWB N/A
- MTVA N/A
- Revenue
- HCWB $3,495,990.00
- MTVA N/A
- Revenue This Year
- HCWB $229.19
- MTVA N/A
- Revenue Next Year
- HCWB N/A
- MTVA N/A
- P/E Ratio
- HCWB N/A
- MTVA N/A
- Revenue Growth
- HCWB 22.27
- MTVA N/A
- 52 Week Low
- HCWB $0.21
- MTVA $1.51
- 52 Week High
- HCWB $2.52
- MTVA $6.75
- Technical
- Relative Strength Index (RSI)
- HCWB 48.72
- MTVA N/A
- Support Level
- HCWB $0.38
- MTVA N/A
- Resistance Level
- HCWB $0.42
- MTVA N/A
- Average True Range (ATR)
- HCWB 0.09
- MTVA 0.00
- MACD
- HCWB -0.00
- MTVA 0.00
- Stochastic Oscillator
- HCWB 4.48
- MTVA 0.00
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.